Fragment-based lead discovery: leads by design

被引:274
作者
Carr, RAE [1 ]
Congreve, M [1 ]
Murray, CW [1 ]
Rees, DC [1 ]
机构
[1] Astex Technol, Cambridge CB4 0QA, England
关键词
D O I
10.1016/S1359-6446(05)03511-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fragment-based lead discovery (also referred to as needles, shapes, binding elements, seed templates or scaffolds) is a new lead discovery approach in which much lower molecular weight (120-250Da) compounds are screened relative to HTS campaigns. Fragment-based hits are typically weak inhibitors (10 mu M-mM), and therefore need to be screened at higher concentration using very sensitive biophysical detection techniques such as protein crystallography and NMR as the primary screening techniques, rather than bioassays. Compared with HTS hits, these fragments are simpler, less functionalized. compounds with correspondingly lower affinity. However, fragment hits typically possess high 'ligand efficiency' (binding affinity per heavy atom) and so are highly suitable for optimization into clinical candidates with good drug-like properties.
引用
收藏
页码:987 / 992
页数:6
相关论文
共 40 条
[1]   Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets [J].
Baurin, N ;
Aboul-Ela, F ;
Barril, X ;
Davis, B ;
Drysdale, M ;
Dymock, B ;
Finch, H ;
Fromont, C ;
Richardson, C ;
Simmonite, H ;
Hubbard, RE .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2004, 44 (06) :2157-2166
[2]   Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening [J].
Boehm, HJ ;
Boehringer, M ;
Bur, D ;
Gmuender, H ;
Huber, W ;
Klaus, W ;
Kostrewa, D ;
Kuehne, H ;
Luebbers, T ;
Meunier-Keller, N .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (14) :2664-2674
[3]   A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design [J].
Card, GL ;
Blasdel, L ;
England, BP ;
Zhang, C ;
Suzuki, Y ;
Gillette, S ;
Fong, D ;
Ibrahim, PN ;
Artis, DR ;
Bollag, G ;
Milburn, MV ;
Kim, SH ;
Schlessinger, J ;
Zhang, KYJ .
NATURE BIOTECHNOLOGY, 2005, 23 (02) :201-207
[4]   A rule of three for fragment-based lead discovery? [J].
Congreve, M ;
Carr, R ;
Murray, C ;
Jhoti, H .
DRUG DISCOVERY TODAY, 2003, 8 (19) :876-877
[5]   Detection of ligands from a dynamic combinatorial library by X-ray crystallography [J].
Congreve, MS ;
Davis, DJ ;
Devine, L ;
Granata, C ;
O'Reilly, M ;
Wyatt, PG ;
Jhoti, H .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (37) :4479-4482
[6]   NMR-based screening with competition water-ligand observed via gradient spectroscopy experiments: Detection of high-affinity ligands [J].
Dalvit, C ;
Fasolini, M ;
Flocco, M ;
Knapp, S ;
Pevarello, P ;
Veronesi, M .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (12) :2610-2614
[7]   Custom chemical microarray production and affinity fingerprinting for the S1 pocket of factor VIIa [J].
Dickopf, S ;
Frank, M ;
Junker, HD ;
Maier, S ;
Metz, G ;
Ottleben, H ;
Rau, H ;
Schellhaas, N ;
Schmidt, K ;
Sekul, R ;
Vanier, C ;
Vetter, D ;
Czech, J ;
Lorenz, M ;
Matter, H ;
Schudok, M ;
Schreuder, H ;
Will, DW ;
Nestler, HP .
ANALYTICAL BIOCHEMISTRY, 2004, 335 (01) :50-57
[8]   In situ assembly of enzyme inhibitors using extended tethering [J].
Erlanson, DA ;
Lam, JW ;
Wiesmann, C ;
Luong, TN ;
Simmons, RL ;
DeLano, WL ;
Choong, IC ;
Burdett, MT ;
Flanagan, WM ;
Lee, D ;
Gordon, EM ;
O'Brien, T .
NATURE BIOTECHNOLOGY, 2003, 21 (03) :308-314
[9]   Fragment-based drug discovery [J].
Erlanson, DA ;
McDowell, RS ;
O'Brien, T .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (14) :3463-3482
[10]   Tethering: Fragment-based drug discovery [J].
Erlanson, DA ;
Wells, JA ;
Braisted, AC .
ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE, 2004, 33 :199-223